Candel surges as prostate cancer therapy meets main goal of late-stage study

Candel Therapeutics

11/12/2024 12:22

** Shares of drug developer Candel Therapeutics  CADL.O 
more than double to $10.17 premarket
    ** Company says its cancer therapy CAN-2409 met the main
goal of a late-stage trial in patients with a type of prostate
cancer
    ** CAN-2409, along with radiation therapy, showed a
statistically significant improvement in disease-free survival
vs radiation therapy alone - CADL
    ** Disease-free survival is the length of time after
treatment that a patient survives without any signs or symptoms
of the disease
    ** Up to last close, stock up 213.6% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com))